Davis, R., Riesenberg, R., Laskowitz, D., Guptill, J., Sanders, L., Cooney, J., … Vanover, K. (2019). ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson's Disease: Results from A Phase I/II Clinical Study. In NEUROLOGY (Vol. 92). Philadelphia, PA: LIPPINCOTT WILLIAMS & WILKINS.

Davis, Robert, Robert Riesenberg, Daniel Laskowitz, Jeff Guptill, Laurie Sanders, Jeffrey Cooney, Andrew Satlin, et al. “ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson's Disease: Results from A Phase I/II Clinical Study.” In NEUROLOGY, Vol. 92. LIPPINCOTT WILLIAMS & WILKINS, 2019.

Davis R, Riesenberg R, Laskowitz D, Guptill J, Sanders L, Cooney J, et al. ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson's Disease: Results from A Phase I/II Clinical Study. In: NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2019.

Davis, Robert, et al. “ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson's Disease: Results from A Phase I/II Clinical Study.” NEUROLOGY, vol. 92, no. 15, LIPPINCOTT WILLIAMS & WILKINS, 2019.

Davis R, Riesenberg R, Laskowitz D, Guptill J, Sanders L, Cooney J, Satlin A, O’Brien J, Duthiel S, Cruz S, Hendrick J, Li P, Wennogle L, Glass S, Pinho M, Taylor E, Kozauer S, Weingart M, Mates S, Snyder G, Vanover K. ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson's Disease: Results from A Phase I/II Clinical Study. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2019.